On the other hand, treatment with RVS or PTS resulted in a 52% or 62% reduction in NLRP3, respectively, as well as a decrease in IL-1β levels, by 28% and 24%, respectively, in respect to the DCM group. The gene discussed is NLRP3; the disease is familial dilated cardiomyopathy.